Wockhardt An Avoidable Name In Pharma Space: SV Prasad
PUBLISHED ON: August 8, 2016 | Duration: 26 min, 51 sec
SV Prasad of Chime Consulting says investors should stay away from Wockhardt shares. High volatility, lack of earnings visibility and quality issues are likely to weigh on the stock, he said.
